VELNACRINE MALEATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H14N2O.C4H4O4
Molecular Weight	330.3352
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.NC1=C2C=CC=CC2=NC3=C1C(O)CCC3

InChI

InChIKey=NEEKVKZFYBQFGT-BTJKTKAUSA-N

InChI=1S/C13H14N2O.C4H4O4/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13;5-3(6)1-2-4(7)8/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Molecular Formula	C13H14N2O
Molecular Weight	214.2631
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.google.com/patents/US4631286 | http://adisinsight.springer.com/drugs/800000572 | https://www.ncbi.nlm.nih.gov/pubmed/15106259

Velnacrine (9-amino-1,2,3,4-tetrahydroacridin-1-ol) is an inhibitor of acetylcholinesterase. It was studied for the treatment of Alzheimer's disease however development was discontinued. There has been no research into the use of velnacrine as a cognitive enhancer in the treatment of Alzheimer's disease since 1994. The FDA peripheral and CNS drug advisory board voted unanimously against recommending approval. This review shows the toxic nature of velnacrine, and provides no evidence of efficacy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Acetylcholinesterase 207 Target ID: CHEMBL220 Sources: http://adisinsight.springer.com/drugs/800000572 \| https://www.google.com/patents/US4631286	Inhibitor 8297		0.79 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 272 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15106259	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Velnacrine for the treatment of Alzheimer's disease (a double-blind, placebo-controlled trials): 10, 25, 50 and 75 mg t.i.d. The 225 mg/day dose appears to be safe for use in multicenter outpatient trials of velnacrine efficacy in Alzheimer's disease.

Route of Administration: Oral

In Vitro Use Guide

Human erythrocyte suspensions were incubated with acetylcholine and choline in the absence or presence of 10 microM atropine or 10 microM velnacrine maleate.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:38:14 GMT 2023` Edited by `admin` on `Fri Dec 15 15:38:14 GMT 2023`
Record UNII	YY1JW04JCB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VELNACRINE MALEATE

Official Name

English

VELNACRINE MALEATE [MART.]

Common Name

English

P-83-6029A

Code

English

P83 6029A

Code

English

HP-029

Code

English

VELNACRINE MALEATE [USAN]

Common Name

English

VELNACRINE MALEATE [MI]

Common Name

English

Velnacrine maleate [WHO-DD]

Common Name

English

P-836029A

Code

English

(±)-9-AMINO-1,2,3,4-TETRAHYDRO-1-ACRIDINOL MALEATE (1:1) (SALT).

Common Name

English

MENTANE

Brand Name

English

1-ACRIDINOL, 9-AMINO-1,2,3,4-TETRAHYDRO-, (±)-, (Z)-2-BUTENEDIOATE (1:1) (SALT)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47792